Strategic Partnerships MPP actively engages with a wide range of stakeholders including civil society, governments, international organisations, industry, and patient groups to license and pool intellectual property. This presents a clear opportunity to tailor outreach to pharmaceutical and biotech partners interested in voluntary licensing or collaborations to expand access in LMICs.

Licensing Expansion With 22 patent holders and a diverse portfolio across HIV, hepatitis C, tuberculosis, cancer, long-acting technologies, obstetric medicines, and COVID-19 treatments, there is potential to upsell broader licensing discussions with existing licensees and attract new licensors seeking CSR-aligned access programs.

Public Funding Leverage MPP is backed by major funders (Unitaid, SDC, Canada, WIPO, others) and works on COVID-19 initiatives with additional government support. This funding structure can be leveraged to position co-financed deals, government-backed distribution pilots, and grant-supported market entry programs for low- and middle-income markets.

Market Access Demand Recent activity and public appearances at major conferences (AIDS 2026, ICASA, AFRAVIH) indicate active engagement in high-visibility disease areas. This signals demand for affordable access solutions and could be a channel to propose regional licensing partnerships, distribution agreements, and supply chain collaborations.

Growth Opportunities The portfolio includes COVID-19 oral antivirals and new influenza antiviral baloxavir marboxil through Roche, plus collaborations with SwiftPharma on STI prevention projects. These areas align with ongoing global health needs and offer cross-sell opportunities for additional licensing deals, co-development, and formulation/packaging partnerships aimed at expanding access.